Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 294

1.

[Hypertension--does it matter how blood pressure is lowered?].

Mehlsen J.

Ugeskr Laeger. 2008 Sep 1;170(36):2782-4. Danish.

PMID:
18761872
2.

Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.

Sever PS, Poulter NR, Dahlof B, Wedel H; ASCOT Investigators.

J Hypertens. 2009 May;27(5):947-54. doi: 10.1097/HJH.0b013e328326cb1a.

PMID:
19318984
3.

Coronary heart disease benefits from blood pressure and lipid-lowering.

Sever PS, Poulter NR, Mastorantonakis S, Chang CL, Dahlof B, Wedel H; ASCOT Investigators.

Int J Cardiol. 2009 Jun 26;135(2):218-22. doi: 10.1016/j.ijcard.2009.01.036. Epub 2009 Feb 20.

PMID:
19232755
4.

The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT1.

Lindgren P, Buxton M, Kahan T, Poulter NR, Dahlöf B, Sever PS, Wedel H, Jönsson B; ASCOT investigators.

Pharmacoeconomics. 2009;27(3):221-30. doi: 10.2165/00019053-200927030-00005.

PMID:
19354342
5.
6.

Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial).

Poulter NR, Dobson JE, Sever PS, Dahlöf B, Wedel H, Campbell NR; ASCOT Investigators.

J Am Coll Cardiol. 2009 Sep 22;54(13):1154-61. doi: 10.1016/j.jacc.2009.04.087.

8.

Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study).

Erdine S, Ro YM, Tse HF, Howes LG, Aguilar-Salinas CA, Chaves H, Guindy R, Chopra P, Moller RA, Schou IM; Gemini-AALA Investigators.

J Hum Hypertens. 2009 Mar;23(3):196-210. doi: 10.1038/jhh.2008.114. Epub 2008 Sep 18.

PMID:
18800143
9.

Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients--an Anglo-Scandinavian cardiac outcomes trial substudy.

Dolan E, Stanton AV, Thom S, Caulfield M, Atkins N, McInnes G, Collier D, Dicker P, O'Brien E; ASCOT Investigators.

J Hypertens. 2009 Apr;27(4):876-85. doi: 10.1097/HJH.0b013e328322cd62.

PMID:
19516185
11.

Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen.

Lindgren P, Buxton M, Kahan T, Poulter NR, Dahlöf B, Sever PS, Wedel H, Jönsson B; ASCOT trial investigators.

Heart. 2008 Feb;94(2):e4. Epub 2007 Oct 4.

PMID:
17916665
12.

Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.

Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O'Rourke M; CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee.

Circulation. 2006 Mar 7;113(9):1213-25. Epub 2006 Feb 13.

13.

Results of the ASCOT-BPLA trial: no practical implications for treatment of hypertension.

[No authors listed]

Prescrire Int. 2006 Jun;15(83):112.

PMID:
16764103
14.

Atorvastatin and amlodipine co-treatment in ASCOT--LLA shows benefit.

[No authors listed]

Cardiovasc J S Afr. 2007 Jan-Feb;18(1):43-4. No abstract available.

15.

Vascular protection of dual therapy (atorvastatin-amlodipine) in hypertensive patients.

Martín-Ventura JL, Tuñon J, Duran MC, Blanco-Colio LM, Vivanco F, Egido J.

J Am Soc Nephrol. 2006 Dec;17(12 Suppl 3):S189-93. Review.

16.

[The most recent study into blood pressure lowering by amlodipine: the beginning of the end for the beta-blockers].

van den Meiracker AH, van Montfrans GA.

Ned Tijdschr Geneeskd. 2006 Apr 22;150(16):886-8. Dutch. Erratum in: Ned Tijdschr Geneeskd. 2006 May 13;150(19):1100.

PMID:
16686086
17.

A new dimension in hypertension management with the amlodipine/perindopril combination.

Poulter NR.

J Hypertens. 2011 Dec;29 Suppl 1:S15-21. doi: 10.1097/01.hjh.0000410248.04963.a4.

PMID:
22157563
18.

Treatment with amlodipine and atorvastatin have additive effect in improvement of arterial compliance in hypertensive hyperlipidemic patients.

Leibovitz E, Beniashvili M, Zimlichman R, Freiman A, Shargorodsky M, Gavish D.

Am J Hypertens. 2003 Sep;16(9 Pt 1):715-8.

PMID:
12944027
19.

Additive beneficial effects of amlodipine and atorvastatin in reversing advanced cardiac hypertrophy in elderly spontaneously hypertensive rats.

Lu JC, Cui W, Zhang HL, Liu F, Han M, Liu DM, Yin HN, Zhang K, Du J.

Clin Exp Pharmacol Physiol. 2009 Nov;36(11):1110-9. doi: 10.1111/j.1440-1681.2009.05198.x. Epub 2009 Apr 27.

PMID:
19413592
20.

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.

Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT Investigators.

Lancet. 2005 Sep 10-16;366(9489):895-906.

PMID:
16154016

Supplemental Content

Support Center